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Abstract

Berberine-INF55 hybrids are a promising class of antibacterials that combine berberine and the NorA
multidrug resistance pump inhibitor INF55 (5-nitro-2-phenylindole) together in one molecule via a
chemically stable linkage. Previous studies demonstrated the potential of these compounds for countering
efflux-mediated antibacterial drug resistance but they didn't establish whether the compounds function as
originally intended, i.e. with the berberine moiety providing antibacterial activity and the attached INF55
component independently blocking multidrug resistance pumps, thereby enhancing the activity of berberine
by reducing its efflux. We hypothesised that if the proposed mechanism is correct, then hybrids carrying more
potent INF55 pump inhibitor structures should show enhanced antibacterial effects relative to those bearing
weaker inhibitors. Two INF55 analogues showing graded reductions in NorA inhibitory activity compared
with INF55 were identified and their corresponding berberine-INF55 hybrids carrying equivalent INF55
inhibitor structures synthesised. Multiple assays comparing the antibacterial effects of the hybrids and their
corresponding berberine-INF55 analogue combinations showed that the three hybrids all show very similar
activities, leading us to conclude that the antibacterial mechanism(s) of berberine-INF55 hybrids is different
from berberine-INF55 combinations.
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Abstract
Berberine-INF55 hybrids are a promising class of antibacterials that combine berberine and the
NorA multidrug resistance (MDR) pump inhibitor INF55 (5-nitro-2-phenyindole) together in one
molecule via a chemically stable linkage. Previous studies demonstrated the potential of these
compounds for countering efflux-mediated antibacterial drug resistance but they didn’t establish
whether the compounds function as originally intended; i.e. with the berberine moiety providing
antibacterial activity and the attached INF55 component independently blocking MDR pumps,
thereby enhancing the activity of berberine by reducing its efflux. We hypothesized that if the
proposed mechanism is correct then hybrids carrying more potent INF55 pump inhibitor structures
should show enhanced antibacterial effects relative to those bearing weaker inhibitors. Two INF55
analogues showing graded reductions in NorA inhibitory activity compared to INF55 were
identified and their corresponding berberine-INF55 hybrids carrying equivalent INF55 inhibitor
structures synthesised. Multiple assays comparing the antibacterial effects of the hybrids and their
corresponding berberine/INF55 analogue combinations showed that the three hybrids all show very
similar activities, leading us to conclude that the antibacterial mechanism(s) of berberine-INF55
hybrids is different from berberine/INF55 combinations.

Introduction
A promising strategy for countering efflux-mediated antibiotic resistance in bacteria is to coadminister a small molecule multi-drug resistance (MDR) efflux pump inhibitor (EPI) in
combination with an antibacterial.[1] In this strategy, the MDR inhibitor serves to limit efflux of the
antibacterial and raise its intracellular concentrations above sub-lethal levels to enhance
antibacterial potency. Potential clinical disadvantages of the approach, however, include the
requirement for matching pharmacokinetic and physicochemical properties of two structurally
unrelated molecules, along with other co-dosing challenges. One possible solution is to covalently
link the MDR inhibitor and antibacterial components together into a single (non-cleavable) hybrid
molecule.[2-4] Such hybrids carry the potential advantage of delivering equimolar quantities of the
two agents to infection sites whilst avoiding the complications of multi-agent co-dosing.[5]
In 2006 Bremner et al. reported the first such hybrid, termed SS14-O 1 (Fig. 1),[2]
comprising the antibacterial alkaloid berberine substituted at its 13-position via a stable 2'-CH2
linkage to 5-nitro-2-phenyindole 5 (INF55), a well-known inhibitor of the NorA MDR pump in
Staphylococcus aureus.[6] In designing SS14-O 1 it was reasoned that the berberine moiety (a
known substrate for NorA)[7] could show enhanced antibacterial effects (membrane activity and
interactions with DNA)[8] as part of a hybrid due to higher intracellular concentrations arising
through inhibition of NorA-mediated efflux by the appended INF55 5 component. SS14-O 1 was
shown to accumulate in wild-type, norA-knockout and NorA overexpressing strains of S. aureus
and showed higher antibacterial potency than berberine alone or berberine in combination with
INF55 5.[2] A follow-up study explored the effects of varying the relative orientations of the
berberine and INF55 components in hybrids by comparing the activities of isomers SS14-O 1,
SS14-M 2 and SS14-P 3 (Fig. 1).[9] The three isomers showed remarkably similar minimum
inhibitory concentrations (MICs) given their structural differences, which remained essentially
unchanged across wild-type, norA-knockout, and NorA overexpressing S. aureus cells. The three
isomers accumulated in S. aureus cells and showed identical abilities to block Enterococcus

faecalis-mediated killing of the nematode Caenorhabditis elegans in a gastrointestinal infection
model. A key conclusion from these studies was that berberine-INF55 hybrids are not substrates
for NorA, although ethidium bromide uptake/efflux experiments suggested that these hybrids
might block the NorA pump.[9] Another study exploring an SS14-O 1 analogue with an extended
methylene ether linkage (4, Fig. 1) showed that this compound displays similar antibacterial
activity to the other hybrids and that its activity remains consistent across S. aureus strains
expressing varying levels of NorA.[10]
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Fig. 1. (a) Berberine-INF55 hybrid antibacterials 1-4.[2,9,10] (b) INF55 (5-nitro-2-phenylindole) 5,
N-Methyl-INF55 6 and N-Methyl-2-phenylindole 7 and their corresponding berberine-INF55
hybrids 3, 8 and 9.

While the above studies demonstrated the promising antibacterial properties of berberineINF55 hybrids, the observation that the hybrids do not appear to be substrates for NorA cast doubt
on whether the hybrids function as originally intended; i.e. with the INF55 moiety serving to block
NorA MDR pumps (and thus efflux) and the attached berberine moiety providing (enhanced)
antibacterial action. In this current study we further explored whether the proposed mechanism of
the hybrids was indeed underpinning their activity. Central to the study was the hypothesis that if
the proposed mechanisms were at play then a direct correlation should exist between the ability of
structurally distinct INF55-type MDR pump inhibitors to potentiate the antibacterial activity of
berberine when co-administered and the activity of the corresponding berberine/INF55 hybrids. In
other words, INF55-type MDR pump inhibitors that more strongly potentiate the antibacterial
activity of berberine when co-administered should confer a higher level of antibacterial potency to
the corresponding berberine-INF55 hybrids.
Exploring this hypothesis required analogues of INF55 5 that: (1) showed a range of
antibacterial potentiation effects when co-administered with berberine and (2) could be attached at
the berberine 13-position to create hybrids differing only in the structure of the appended INF55
moiety. Checkerboard assays (see below) identified N-Methyl-INF55 6 and N-methyl-2phenylindole 7 as suitable INF55 5 analogues (Fig. 1). This paper reports the synthesis and parallel
evaluation of berberine/INF55 hybrids 3, 8 and 9, which incorporate INF55 5 and analogues 6 and
7, respectively (Fig. 1), and their corresponding berberine/5,6,7 combinations, in multiple assays
aimed at testing the above hypothesis.

Chemistry
The synthesis of INF55 5, analogues 6 and 7 and hybrids 3, 8 and 9 is outlined in Scheme 1. INF55
5 was obtained in 91% yield via regioselective nitration of 2-phenyl indole 10 using the literature
method.[11] N-Methyl-INF55 6 was prepared in 80% yield by stirring INF55 5 for two hours at
room temperature with K2CO3 and CH3I in anhydrous DMF. N-Methyl-2-phenylindole 7 was

prepared in 80% yield by stirring 2-phenylindole 10 for 2 hours in anhydrous THF at room
temperature with NaH and CH3I.
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Scheme 1. Reagents and conditions: (a) NaH, CH3I, THF, 80%; (b) NaNO3, H2SO4, -10 °C,
70%;[11] (c) K2CO3, CH3I, DMF, 80%; (d) PdCl2, 1,4-dioxane, methyl 4-iodobenzoate, 100 °C,
84%; (e) TFA:CH2Cl2 (1:1), 79%; (f) NaNO3, H2SO4, -10 °C;[12] (g) LiBH4, THF, 40 °C;[12] (h)
CBr4, PPh3, THF:Et2O (1:1);[12] (i) NaI (10 mol %), CH3CN, 70 oC, anion exchange 40%; (j) CH3I,
K2CO3, DMF, anion exchange, 75%; (k) PdCl2, methyl 4-iodobenzoate, 1,4-dioxane, 100 °C, 75%;
(l) LiAlH4, THF, 40 °C, 85%; (m) CCl4:CH2Cl2 (1:1), PPh3, ~65% (crude); (n) NaI (10 mol %),
CH3CN, 70 oC, anion exchange, 40%.
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allyldihydroberberine[13] in the final step with the key benzylic bromide intermediate 16; prepared
via functional group manipulations with the precursor methyl ester 13. In the prior work, 13 was
synthesised directly from indole and methyl-4-iodobenzoate in a single step using the rhodium
(III)-catalysed indole C2-arylation method reported by Sames et al.[14] While this reaction
invariably provides some 13, the yields are always low (max 28%) and the reaction outcomes
unpredictable. A more robust Stille coupling-based approach was therefore developed to install the
functionalised 4-carboxymethyl aryl substituent at the indole C2-position. Stille coupling of NBoc-2-tributylstannylindole 11 (prepared in two steps via the literature method)[15] with methyl-4iodobenzoate using PdCl2 in refluxing 1,4-dioxane gave 12 in 84% yield. Boc-deprotection of 12
using CH2Cl2:TFA (1:1) subsequently afforded the NH-indole 13 in 79% yield. While the new
route to 13 is longer, it is simple to carry out and reproducible on a multi-gram scale. The key
intermediate 16 was then obtained from 13 using our reported 3-step nitration, reduction,
bromination sequence.[12]
A new reaction for producing SS14-P 3 was developed wherein bromide 16 was coupled to
8-acetonyldihydroberberine 17[16] instead of 8-allyldihydroberberine, as had been performed
previously.[12] Catalytic Finkelstein conversion of bromide 16 in situ to the iodide with 10 mol%
NaI in CH3CN at 70 oC in the presence of 8-acetonyldihydroberberine 17 gave SS14-P 3 in 40%
yield. Preparative RP-HPLC purification in the presence of 0.1% HCl initially provided mixed Cl/Br-/I- salts that were subsequently converted to pure Cl- salts of 3 by anion exchange (Scheme 1).
Although the new procedure didn’t provide higher yields of SS14-P 3 it was more reproducible than
the 8-allyldihydroberberine method,[12] which for unknown reasons sometimes failed to yield any 3.
SS14-P 3 was converted to the N-methylated hybrid 8 in 75% yield by reaction with excess
CH3I and K2CO3 in DMF at room temperature. The mixture of Cl-/I- salts initially obtained after
silica gel column chromatography (CH3CN:EtOAc:MeOH, 1:1:0.5) was converted to the pure Clsalt 8 by anion exchange. Hybrid 9 was prepared by reacting 8-acetonyldihydroberberine 17 with

the benzylic chloride intermediate 21, which was synthesised in 3 steps from (N-methylindol-2yl)tributylstannane 18 (prepared by the literature method).[15] In the first step, PdCl2 catalysed Stille
coupling of 18 with methyl-4-iodobenzoate provided 19 in 75% yield.
Reduction of the methyl ester 19 with LiAlH4 (added portion wise) in anhydrous THF with
gentle heating at 40 oC gave the benzylic alcohol 20 in 85% yield. Chloride 21 was prepared by
stirring 20 in CCl4:CH2Cl2 (1:1) for 10 min before adding PPh3 (4 eq). TLC analysis
(EtOAc:hexane, 8.5:1.5) was used to monitor the reaction and upon completion the mixture was
quickly filtered through a plug of neutral alumina and washed with CH2Cl2. The filtrates were
concentrated in vacuo and the residue triturated with pentane. The crude 21 was used immediately
due to its instability and was unable to be fully characterised. Reaction of crude 21 with 8acetonyldihydroberberine 17 in the presence of 10 mol% NaI in CH3CN at 70 oC provided hybrid 9
in 40% yield after preparative RP-HPLC and anion exchange.

Checkerboard assays in S. aureus strains with varying NorA expression levels
Preliminary antibacterial checkerboard assays[2] were performed using 8325-4 wild-type, K1758
norA-knockout and K2378 NorA overexpressing S. aureus cells with berberine/5-7 combinations
to confirm their suitability as INF55-based NorA EPIs for use in this study (Fig. 2). Complete
growth inhibition was observed in all three S. aureus strains with INF55 5 at 1.25 g/mL and
berberine present at concentrations below 20 g/mL. Analogues 6 and 7 at 1.25 g/mL did not
inhibit growth of 8325-4 and K1758 cells in the presence of berberine at the highest concentrations
tested (125 µg/mL or 30 µg/mL). Growth inhibition of K2378 cells was observed with 6 and 7 at
1.25 g/mL, but only with berberine present at 125 g/mL. N-Me-INF55 6 did not inhibit 8325-4
growth at the highest concentration tested (80 g/mL) with 125 g/mL berberine present. The
results are consistent with the following rank order of berberine antibacterial potentiation effects
for the compounds: 5 > 7 > 6. The graded reductions in activity confirmed 5-7 were a suitable
series of INF55-based NorA EPIs for testing the above-stated hypothesis.

Fig. 2. Checkerboard assays comparing potentiation of berberine’s antibacterial effects by INF55 5
(♦), 6 (■) and 7 (▲) against (a) 8325-4 wild-type, (b) K1758 norA-knockout and (c) K2378 NorA
overexpressing S. aureus cells. Compounds 5-7 showed no antibacterial effects against these
strains when administered alone at concentrations below or equal to 80 g/mL. MICs for berberine
alone against 8325-4, K1758 and 2378 were 125 g/mL, 30 g/mL and 250 g/mL, respectively.[2]

Antibacterial activities against S. aureus strains
The checkerboard experiments indicated that potentiation of berberine’s activity by the three
INF55-based NorA EPIs 5-7 decreases in the order 5 > 7 > 6 against 8325-4 wild-type, K1758
norA-knockout and K2378 NorA overexpressing S. aureus cells. Accordingly, if the above-stated
hypothesis were correct then their respective hybrids 3, 8 and 9 should show antibacterial potencies
in the order 3 > 9 > 8 against these cells, assuming no synergistic or antagonistic action between
the two components when joined. The MICs for complete inhibition of bacterial growth was
measured for hybrids 3, 8 and 9 against the S. aureus panel with vancomycin included as a control
(Table 1). All three hybrids showed identical MICs (0.78 g/mL) against 8325-4 and K2378 and 2fold higher potencies (0.39 g/mL) against K1758. The MIC of vancomycin was 1 g/mL against
the three strains. Consistent MICs (< 2-fold difference) for 3, 8 and 9 confirmed that they are all
poor substrates for NorA. Lack of variation in MICs was a feature observed previously with
hybrids 1-4 and indicates that the molecular target(s) of berberine-INF55 hybrids is(are) tolerant of
structural variations within the INF55 portion. However, unvarying MICs for hybrids 3, 8 and 9 is

not consistent with the stated hypothesis, since if correct, the MICs would have increased in the
order 3 < 9 < 8.

MIC

S. aureus
strains

Compound

(μg/ml)

3

0.78

8

0.78

9

0.78

vancomycin

1

3

0.39

8

0.39

9

0.39

vancomycin

1

3

0.78

8

0.78

9

0.78

vancomycin

1

8325-4

K1758

K2378

Table 1. MICs of hybrids 3, 8, and 9 and vancomycin (control) against wild-type (8325-4), norAknockout (K1758) and NorA overexpressing (K2378) S. aureus strains.

Uptake into S.aureus cells
Uptake of hybrids 3, 8 and 9, berberine and berberine in the presence of INF55 5 and analogues 6,
7 into 8325-4, K1758 and K2378 S. aureus cells was compared using our previously reported
fluorescence-based method.[9] The interaction of berberine or hybrids with DNA upon entering
cells causes an increase in fluorescence at 517 nm (excitation at 355 nm), while expulsion of these
compounds from cells via efflux leads to lower fluorescence intensities, thus providing a

qualitative measure of compound efflux susceptibility. Fig. 3 indicates that berberine at 3 M alone
does not accumulate significantly in any of the S. aureus strains, consistent with its high efflux
susceptibility. Lack of berberine uptake into norA-knockout strain K1758 suggests that pumps
other than NorA must also contribute to its efflux. Uptake of berberine did not increase in any of
the strains in the presence of equimolar 7 and only small increases were observed withcompounds
5 and 6 present. These results suggest that NorA inhibition by INF55 5 and analogues 6, 7 has only
a minor effect on berberine accumulation, possibly due to the countering effects of other pumps not
affected by these inhibitors. Nevertheless, the ability of INF55 analogues (5 in particular) to
potentiate the antibacterial activity of berberine (Fig. 2) against the same S. aureus strains suggests
that this seemingly slight effect on berberine uptake is sufficient to enhance antibacterial effects.
Significantly larger increases in fluorescence were observed with hybrids 3, 8 and 9 at the
same concentrations (3 M), indicating that they are taken up to a greater extent in these cells than
berberine or berberine in the presence 5-7 (Fig.3). For these experiments it was necessary to
demonstrate that the high fluorescence observed with hybrids was due to increased cellular uptake
and not increased fluorescence intensity of hybrid/DNA complex(es) relative to berberine/DNA
complex(es). Cell-free control experiments comparing fluorescence upon binding to calf thymus
DNA (CT-DNA)[17] of hybrids 3, 8, 9, berberine and berberine in the presence of 5, 6 and 7 showed
that complexes formed between the three hybrids and CT-DNA exhibited significantly less
fluorescence than berberine/DNA complexes (data not shown), supporting the conclusion that
higher intracellular uptake of 3, 8 and 9 had occurred relative to berberine alone or berberine in
mixtures with 5-7.
Uptake of each hybrid was unchanged across the three strains, consistent with the
compounds not being substrates for NorA (in agreement with the MIC data, Table 1). While the
uptake data confirmed that 3, 8 and 9 accumulate in these cells, there was no evidence to support
that incorporation of higher potency INF55-based EPIs leads to increased uptake. If this were true,
uptake of the hybrids should have increased in the order 8 < 9 < 3 (based on the checkerboard data

in Fig. 2). Hybrids 8 and 9 appeared to show identical uptake in all strains that was greater than
that of 3 in spite of 3 containing the most potent NorA EPI 5.

Fig. 3. Uptake of hybrids 3 (◊), 8 (□), 9 (∆), berberine (●) and berberine in the presence of 5 (♦), 6
(■) and 7 (▲) into (a) 8325-4 wild-type, (b) K1758 norA-knockout and (c) K2378 NorA
overexpressing S. aureus cells. Uptake was measured by monitoring fluorescence at 517 nm
(excitation at 355 nm) and is expressed in arbitrary fluorescence units A.U. All compounds were
present at 3 M in 1% DMSO solutions.

Antibacterial activity and checkerboard assays with methicillin-resistant S. aureus (MRSA)
and E. faecalis
Bacterial
strains

MIC
Compound

(μg/ml)

berberine

50

5

> 100

6

> 100

MRSA

7

> 100

MW2

3

3.13

8

3.13

9

< 1.56

vancomycin

< 1.56

berberine

> 100

5

> 100

6

> 100

E. faecalis

7

> 100

MMH594

3

3.13

8

3.13

9

3.13

vancomycin

< 1.56

Table 2. MICs of INF55 5, analogues 6 and 7, hybrids 3, 8 and 9 and vancomycin (control) in
liquid cultures of MRSA MW2 and E. faecalis MMH594.

The above-stated hypothesis was further tested by comparing the curative effects of the
hybrids in two C. elegans live infection models. In these models, C. elegans is infected with
methicillin-resistant S. aureus (strain MW2) or E. faecalis (MMH594) and worm survival is

measured relative to controls. Before performing these experiments it was necessary to measure the
MICs of each compound against S. aureus MW2 and E. faecalis MMH594 cells in liquid cultures
(Table 2). Berberine showed an MIC of 50 µg/mL against MRSA MW2 and lower potency (MIC
100 µg/mL) against E. faecalis MMH594. All three EPIs 5-7 showed no activity against either
strain when administered alone at < 100 µg/mL. Hybrids 3, 8 and 9 on the other hand, all showed
robust but virtually identical activities (MICs 1.56 – 3.13 g/mL). These data once again conflicted
with the hypothesis since MICs for 3, 8 and 9 should have increased in the order 3 < 9 < 8 if it were
supported.

Checkerboard assays were used to compare the berberine potentiation effects of 5-7 in MW2
and MMH594 cells (Fig. 4). As expected, INF55 5 was the most potent EPI with 25 µg/mL and
concentrations of berberine below 10 µg/mL strongly inhibiting MW2. EPIs 6 and 7 required > 50
µg/mL to show any effect. The three EPIs were notably less effective against MMH594, where
concentrations of 5 greater than 50 µg/mL and higher concentrations of berberine were required to
produce an effect. Compound 7 showed only weak activity at 100 µg/mL and required higher
concentrations of berberine. Compound 6 showed no potentiation at the highest concentration
tested. The berberine potentiation activity of the EPIs thus decreased in the order 5 > 7 > 6 against
MW2 and MMH594, in agreement with the order observed with S. aureus strains 8325-4, K1758
and K2378 (Fig. 2). These data supported 5-7 (and their respective hybrids 3, 8 and 9) being
suitable compounds for testing our berberine/INF55 hybrid mechanism hypothesis in the C. elegans
live infection models.

Fig. 4. Checkerboard assays comparing the potentiation of berberine’s antibacterial effects by
INF55 5 (♦) and analogues 6 (■) and 7 (▲) against (a) MRSA MW2 and (b) E. faecalis MMH594.

C. elegans/MRSA and C. elegans/E. faecalis live infection models
The C. elegans/MRSA live infection model measures worm survival after infection with MRSA
MW2.[18] In the absence of antimicrobials the worms die but they can be rescued by treatment with
vancomycin (Fig. 5(a), Vanc 20 g/mL). Increasing concentrations (0-200 g/mL) of berberine,
EPIs 5-7 and hybrids 3, 8 and 9 were used to investigate their effects on MRSA MW2-infected
worm survival. Berberine was found to increase survival relative to the 1% DMSO control at
concentrations above 50 µg/mL, consistent with its MIC (50 g/mL) against this species (Table 2).
None of the EPIs showed any curative effects when tested alone. Hybrids 3, 8 and 9, however, all
showed robust curative effects, but there were no clear differences between their potencies.
Checkerboard survival assays where berberine was co-administered with EPIs 5-7 to worms
infected with MRSA were attempted but reproducible data were unable to be obtained, possibly due
to the toxicity of INF55-based EPIs to worms.[2]

Fig. 5. Survival (%) of C. elegans worms infected with (a) MRSA MW2 and (b) E. faecalis
MMH594 following treatment with increasing concentrations of berberine, INF55 5 and analogues
6, 7 and hybrids 3, 8, and 9. Vancomycin (Vanc, 20 g/mL) and tetracycline (Tet, 20 g/mL) were
included as positive controls in the MRSA and E. faecalis experiments, respectively, and 1%

DMSO as a negative control. Compound concentrations are in g/mL. All assay solutions contained
1% DMSO.
In the C. elegans/E. faecalis live infection model[9] worms are infected with E. faecalis
MMH594 and their survival monitored over several days. In the absence of antimicrobials the
worms die but they can be rescued with tetracycline (Fig. 5(b), Tet 20 g/mL). Berberine and EPIs
5-7 alone showed no effect on survival over the concentration range tested (0-200 µg/mL). The lack
of activity of berberine against E. faecalis MMH594 was consistent with its low in vitro potency
against this organism (MIC > 100 µg/mL, Table 2). The three hybrids 3, 8 and 9 all showed strong
rescuing effects at concentrations above 6.25µg/mL, but once again there were no clear differences
between their potencies. As with the MRSA MW2 model, checkerboard experiments were
attempted with berberine/ 5-7 combinations but reproducible data were unable to be obtained.

Concluding Remarks
This study aimed to test the hypothesis that berberine-INF55 hybrids elicit their antibacterial effects
through the combined activities of their two functionally distinct components, with the berberine
moiety acting to kill bacterial cells and the INF55 portion serving to block NorA-mediated efflux.
Checkerboard assays with three S. aureus strains varying in NorA expression levels, along with
MRSA MW2 and E. faecalis MMH594 strains, established that INF55 analogues 6 and 7 show
graded reductions in their berberine potentiation potencies relative to 5, thus making them suitable
compounds for testing the hypothesis. The three EPIs and their corresponding hybrids 3, 8 and 9
were synthesised using a mix of literature and newly developed chemistry.
The three hybrids showed strong antibacterial activity (measured as MICs) against all strains
tested but the activity did not vary between the compounds, a result inconsistent with the
hypothesis. Uptake of the three hybrids into S. aureus cells was confirmed using fluorescence-based
cell assays but again the lack of variation in uptake did not support the hypothesis. The C. elegans
MRSA and E. faecalis live infection experiments clearly demonstrated the robust curative effects of

the hybrids, with worm survival also establishing that the compounds show low toxicity. However,
failure to observe significant differences between their activities was further evidence that the
hypothesis was not supported. We conclude from this work that the mechanism(s) of antibacterial
action of berberine/INF55 hybrids must be different from the mechanisms at play when berberine is
co-administered with INF55-based EPIs. Further studies aimed at unravelling the true mechanism
of action of this interesting class of antibacterials are therefore warranted.

Experimental
Chemistry
THF and diethyl ether were dried over sodium and DMF and CH3CN was dried over 4 Å molecular
sieves prior to use. 2-Phenylindole 10, CH3I, Sn(Bu)3Cl, n-butyllithium, PdCl2, CBr4, PPh3,LiAlH4,
LiBH4 and IRA-904 quaternary ammonium Cl- anion exchange resin were purchased from Sigma
Aldrich. 4-Iodomethylbenzoate was synthesised by MeOH/H2SO4(cat) esterification of 4iodobenzoic acid, which was purchased from Matrix scientific. Analytical thin layer
chromatography (TLC) was carried out using Merck 0.2 mm silica gel 60 F254 coated aluminium
plates. Compounds were visualised by UV absorption (λ 254 nm) and/or staining with cerium
ammonium molybdate. Column chromatography was performed using Merck silica gel 60 (230-400
mesh). Low resolution electrospray ionisation mass spectra (ESI-MS) were obtained on a
micromass Z-path (LCZ) spectrometer. Electron impact high resolution mass spectra (HRMS) were
obtained on a Fisions/VG Autospec spectrometer using perfluorokerosene as internal standard. ESI
HRMS were obtained on a Waters QT Ultima spectrometer using polyethylene glycol or
polypropylene glycol as internal standard. 1H,
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C NMR experiments were performed using a

Varian Mercury 300 MHz, Varian Inova 500 MHz or Varian Premium Shielded 500 MHz
spectrometer at 25 oC. Chemical shifts are reported as δ (ppm) relative to internal TMS (or solvent
where indicated). The abbreviations s = singlet, d = doublet, appt = apparent triplet, t = triplet, q =
quadruplet, m = multiplet and bs = broad singlet are used throughout. RP-HPLC purifcations of

hybrids 3 and 9 were performed using gradient elutions with solvents A (100% H2O, 0.1% HCl)
and B (90% CH3CN, 10% H2O, 0.1% HCl) on a Sunfire TM Prep C18 OBDTM (5µM) steel jacketed
column run at 30 mL.min-1 and detection at 254 nm. Analytical HPLC analyses were performed
using a Shimadzu CLASS-LC10 VP system using gradient elutions with solvent A and B on a
Phenomenex Luna µM C18 column run at 1mL.min-1 with detection at 254 nm.

9,10-dimethoxy-13-(4-(5-nitro-1H-indol-2-yl)benzyl)-5,6-dihydro-[1,3]diolo[4,5-]isoquinolino[3,2a]isoquinolin-7-ium chloride 3
To a stirred solution of key bromide 16 (100 mg, 0.30 mmol) in anhydrous CH3CN (10 mL) was
added sodium iodide (49 mg, 0.33mmol) and the mixture stirred for 1 h at 70 oC. 8-Acetonyl
dehydroberberine 17 (118.8 mg, 0.30 mmol) was then added and stirring continued at 70 oC for
another 3-4 h. The reaction was monitored by TLC (MeOH:CHCl3, 1:9 or EtOAc:hexane, 1:4) and
ESI-MS. After completion, the reaction was diluted with CH3CN (5 mL) and the product adsorbed
onto silica gel via evaporation of the solvent. Purification was performed using column
chromatography (EtOAc:CH3CN:hexane, 1:1:1) initially followed by (EtOAc:CH3CN:MeOH,
1:1:0.3) to afford semi pure 3. Further purification was carried out using RP-HPLC (gradient from
A 0% to 100% B over 30 min, Rt = 18.8 min). Fractions containing the product were combined and
concentrated by freeze-drying. The salt mixture obtained was stirred with IRA-904 quaternary
ammonium Cl- anion exchange resin in MeOH (5 mL) at rt for 1 h. Filtration and concentration
yielded pure 3 as a yellow amorphous solid. (75 mg, 40%). mp 218-220 °C (decomp);1HNMR (500
MHz, DMF-d6): δ 3.26 (s, 2H), 4.03 (s, 3H), 4.11 (s, 3H), 4.84 (s, 2H), 5.15 (bs, 2H), 6.06 (s, 2H),
7.04 (s, 1H), 7.11 (s, 1H), 7.17 (s, 1H), 7.32 (d, J = 7.5 Hz, 2H), 7.62 (d, J = 9.0 Hz, 1H), 7.81-7.93
(m, 3H), 8.07 (m, 2H), 8.46 (s, 1H), 10.1 (s, 1H), 13.05 (s, 1H); 13C NMR (125 MHz, DMF-d6): δ
28.3, 36.3, 57.4, 58.1, 62.5, 101.3, 103.1, 109.1, 112.4, 117.4, 121.2, 122.4, 122.5, 126.8, 127.0,
128.9, 129.5, 130.8, 131.0, 133.9, 135.0, 138.4, 140.3, 141.6, 142.0, 142.1, 145.4, 146.2, 147.5,
150.4, 151.2, ESI-MS m/z Calc for C35H28N3O6+ 586.1973; observed 586.1997.

1-Methyl-5-nitro-2-phenyl-1H-indole 6
To a stirred solution of INF55 5 (1g, 4.2 mmol) in anhydrous DMF (10 mL) was added oven dried
K2CO3 (1.74 g, 12.6 mmol) and stirred for 15-20 min at rt. Methyl iodide (0.8 mL, 12.6 mmol) in
DMF (5 mL) was then added dropwise at rt and stirred for 1-2 h. Progress of the reaction was
monitored by TLC (EtOAc:Hexane, 1:4). The reaction mixture was diluted with water and extracted
with EtOAc (3 x 10 mL), the organic layer was washed with water and brine and dried over
anhydrous Na2SO4 before concentrating in vacuo to afford 6 as a yellow solid (847 mg, 80%). mp
175-178 oC; 1H NMR (300 MHz, CDCl3): δ 3.80 (s, 3H), 6.71 (s, 1H), 7.37 (d, J = 6.0 Hz, 1H),
7.48-7.51 (m, 5H), 8.14 (d, J = 6.0 Hz, 1H), 8.58 (s, 1H);
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C NMR (75 MHz, CDCl3): δ 31.9,

103.7, 109.4, 117.2, 117.5, 127.0, 128.7, 129.3, 131.4, 140.9, 141.8, 144.7. ESI-MS m/z Calc. for
C15H13N2O2 [M+H+] 253.0977; observed 253.0970.

1-Methyl-2-phenyl-1H-indole 7
To a stirred solution of 2-phenylindole 5 (1.0 g, 5.2 mmol) in anhydrous THF (10 mL) was added
sodium hydride (372 mg, 15.5 mmol) and the reaction was stirred for 15 min at rt. Methyl iodide
(2.20 g, 15.5 mmol) in anhydrous THF (10 mL) was added dropwise to the reaction mixture and
stirred for 2 h. The reaction was monitored by TLC (EtOAc:Hexane, 1:9). The reaction mixture was
quenched with saturated sodium sulphate and extracted with EtOAc (3 x 10 mL). The organic layer
was separated, dried over anhydrous MgSO4 and concentrated in vacuo to afford 7 as a white solid
(857 mg, 80%). mp 110-112 oC; 1H NMR (500 MHz, CDCl3): δ 3.86 (s, 3H), 6.54 (s, 1H), 7.12 (t, J
= 8.0 Hz, 1H), 7.22 (t, J = 7.0 Hz, 1H), 7.30-7.36 (m, 2H), 7.40-7.48(m, 4H), 7.61 (d, J = 7.5 Hz,
1H); 13C NMR (125 MHz, CDCl3): δ 31.1, 101.7, 109.6, 119.2, 120.5, 121.7, 127.8, 128.0, 128.5,
129.4, 132.8, 138.4, 141.6; ESI-MS m/z Calc for C15H14N [M+H+] 208.1126; observed 208.1126.

9,10-dimethoxy-13-(4-(1-methyl-5-nitro-1H-indol-2-yl)benzyl)-5,6-dihydro-[1,3]dioxolo[4,5g]isoquinolino[3,2-a]isoquinolin-7-ium chloride 8
To a stirred solution of hybrid 3 (70 mg, 1.1 mmol) in anhydrous DMF (5 mL) under Ar was added
oven-dried K2CO3 (464 mg, 3.4 mmol) and the mixture was stirred for 15 min. Methyl iodide (0.21
mL, 3.4 mmol) in DMF (2 mL) was added dropwise to the reaction and stirring continued for a
further 1-2 h. Upon complete consumption of the starting material (ESI-MS) the mixture was
concentrated in vacuo and the residue purified by silica gel flash column chromatography
(CH3CN:EtOAc:MeOH, 1:1:0.5) to yield mixed Cl-/I- salts. The salt mixture was stirred with IRA904 quaternary ammonium Cl- anion exchange resin in MeOH (5 mL) at rt for 1 h. After filtration
and concentration the title compound 8 was obtained as a yellow amorphous solid (53.3 mg, 75%).
mp 208-212 °C (decomp); 1H NMR (500 MHz, DMF-d6): δ 3.34 (s, 2H), 3.91 (s, 3H), 4.15 (s, 3H),
4.21 (s, 3H), 5.00 (s, 2H), 5.18 (bs, 2H), 6.17 (s, 2H), 6.92 (s, 1H), 7.16 (s, 1H), 7.29 (s, 1H), 7.48
(d, J = 6.5 Hz, 2H), 7.71 (d, J = 7.5 Hz, 2H), 7.75 (d, J = 8.5 Hz, 1H), 8.01 (m, 1H), 8.11 (d, J = 8.5
Hz,1H), 8.18 (d, J = 9.0 Hz,1H), 8.59 (s, 1H), 10.40 (s, 1H); 13C NMR (125 MHz, DMF-d6): δ 28.3,
32.2, 36.2, 57.4, 58.0, 62.6, 103.1, 104.4, 109.1, 109.2, 111.2, 117.3, 117.6, 121.1, 122.5, 122.5,
126.8, 127.6, 129.4, 130.6, 130.9, 133.9, 135.2, 138.5, 140.9, 141.9, 142.2, 145.1, 145.6, 146.8,
147.6, 150.4, 151.3; ESI-MS m/z Calc for C36H30N3O6 [M-Cl-] 600.2129; observed 600.2122.

9,10-dimethoxy-13-(4-(1-methyl-1H-indol-2-yl)benzyl)-5,6-dihydro-[1,3]dioxolo[4,5g]isoquinolino[3,2-a]isoquinolin-7-ium chloride 9
To a solution of the crude chloride 21 (128 mg, 0.5 mmol) in anhydrous CH3CN (10 mL) was
added sodium iodide (12.7 mg, 0.53 mmol) and the reaction was stirred for 1 h at 70 oC. 8acetonyldihydroberberine 17 (196.8 mg, 0.501mmol) was then added and stirring continued for
another 3-4 h at 70 oC. The reaction was monitored by TLC (EtOAc:Hexane, 1:4) to observe
consumption of the chloride, and also by ESI-MS. Upon completion of the reaction the mixture was
purified by silica gel column chromatography using EtOAC:CH3CN:hexane (1:1:2) followed by

EtOAc:CH3CN:MeOH (1:1:0.1). The semi-pure material was further purified by preparative RPHPLC using a gradient from 0% A to 100% B over 30 min (Rt = 21.5 min). The fractions
containing pure product were pooled and concentrated by freeze-drying to yield 9 as a yellow solid
(118 mg, 40%). mp 186-189 oC; 1H NMR (500 MHz, DMF-d6): δ 3.37 (s, 2H), 3.83 (s, 3H), 4.15
(s, 3H), 4.23 (s, 3H), 5.01 (s, 2H), 5.22 (bs, 2H), 6.20 (s, 2H), 6.63 (s, 1H), 7.10 (appt, J = 7.5 Hz,
1H), 7.20-7.25 (m, 3H), 7.48 (d, J = 7.5 Hz, 2H), 7.53 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H),
7.69 (d, J = 8.0 Hz, 2H), 8.04 (d, J = 7.5 Hz, 1H), 8.22 (d, J = 7.5 Hz, 1H) 9.42 (s, 1H); 13C NMR
(125 MHz, DMF-d6): δ 28.3, 31.5, 36.2, 57.4, 58.2, 62.6, 102.1, 103.1, 109.1, 109.2, 110.6, 120.2,
120.8, 121.1, 122.2, 122.4, 122.5, 126.8, 128.6, 129.2, 130.4, 131.1, 131.9, 134.0, 135.1, 138.5,
139.3, 139.9, 141.4, 145.5, 146.5, 147.6, 150.4, 151.2; ESI-MS m/z Calc. for C36H31N2O4+ [M-Cl-]
555.2278; observed 555.2289.

Tert-butyl-2-(4-(methoxycarbonyl)phenyl)-1H-indole-1-carboxylate 12
To a stirred solution of 11 (5 g, 9.9 mmol) in anhydrous 1,4-dioxane (50 mL) was added 4iodomethylbenzoate (2.04 g, 7.78 mmol), palladium(II) chloride (43 mg, 0.24 mmol) and the
reaction mixture was purged with nitrogen for 15 min. The reaction mixture was then heated to 100
o

C and stirred for one 1h while monitoring by TLC (EtOAc:Hexane, 1:9). The reaction mixture was

cooled, diluted with EtOAc (100 mL) and stirred over 15% aqueous potassium fluoride (300 mL)
for 15 min. The precipitate was removed by filtration and washed well with EtOAc (200 mL). The
organic layer was separated, washed with water and brine, dried over anhydrous Na2SO4 and
concentrated in vacuo. The residue was purified by silica gel column chromatography
(EtOAc:Hexane, 1.5:8.5) to afford 12 as a white semi-solid (2.3 g, 84%). mp 79-83 oC; 1H NMR
(500 MHz, CDCl3): δ 1.32 (s, 9H), 3.94 (s, 3H), 6.6 (s, 3H), 7.2 (appt, J = 7.5 Hz, 1H), 7.35 (appt, J
= 7.5 Hz, 1H), 7.50 (d, J = 7.5 Hz, 2H), 7.56 (d, J = 7.5 Hz, 1H), 8.07 (d, J = 7.5 Hz, 2H), 8.21 (d, J
= 8.5 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ 27.6, 52.1, 83.8, 110.7, 115.2, 123.4, 125.1, 128.3,

128.8, 129.0, 129.2, 137.9, 139.4, 149.9, 166.86. ESI-MS m/z Calc. for C21H21NNaO4 [M+Na+]
374.1368, found 374.1368.

Methyl 4-(1H-indol-2-yl)benzoate 13
To a stirred solution of 12 (2.3 g, 6.6 mmol) in anhydrous CH2Cl2 (7 mL) was added trifluoroacetic
acid (7 mL) and the reaction mixture was stirred for 1-2 h. The mixture was concentrated in vacuo
and the residue redissolved in ethyl acetate (100 mL). The EtOAc layer was washed with water and
brine and dried over anhydrous Na2SO4 before concentrating in vacuo. The residue was purified by
flash column chromatography (EtOAc:Hexane, 1:2) to afford 13 as an off-white crystalline solid
(1.3 g, 79%). mp 204-205 °C; 1H NMR (500 MHz, CD3COCD3): δ 3.90 (s, 3H); 7.029-7.059 (m,
2H), 7.14 (appt, J = 7.0 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.96 (d, J = 8.5
Hz, 2H), 8.05 (d, J = 8.5 Hz, 2H), 11.01 (bs, 1H); 13C NMR (125 MHz, CD3COCD3): δ 52.2, 101.8,
U

112.2, 120.6, 121.4, 123.3, 125.6, 129.3, 129.9, 130.8, 137.3, 137.8, 138. 8, 166.9. ESI-MS m/z
Calc for C16H14NO2 [M+H+] requires 252.1025; found 252.1014.

Methyl 4-(1-methyl-1H-indol-2-yl)benzoate 19
A stirring solution of (N-methylindol-2-yl)tributylstannane 18 (5.0 g, 11.9 mmol) in anhydrous THF
was charged with methyl-4-iodobenzoate (2.18 g, 8.3 mmol) and PdCl2 (97.6 mg, 0.832 mmol). The
reaction mixture was purged with nitrogen for 30 min and then heated at reflux for 3-4 h with
monitoring by TLC (EtOAc:Hexane, 1:5). The crude reaction mixture was adsorbed onto silica gel
and purified by flash column chromatography with Pet. spirit:EtOAc (9.5:0.5 to 8:2) to yield 19 as
an off-white solid (2.36 g, 75%). mp 105 oC; 1H NMR (500 MHz, CDCl3): δ 3.75 (s, 3H), 3.94 (s,
3H), 6.63 (s, 1H), 7.15 (appt, J = 7.5 Hz, 1H), 7.26 (appt, J = 7.5 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H),
7.58 (d, J = 8.5 Hz, 2H), 7.64 (d, J = 7.5 Hz, 1H), 8.12 (d, J = 9.8 Hz, 2H); 13C NMR (125 MHz,
(CDCl3): δ 31.3, 52.1, 102.8, 109.7, 120.1, 120.7, 122.2, 127.8, 128.9, 129.2, 129.7, 137.2, 138.6,
140.1, 166.7; ESI-MS m/z Calc for C17H16NO2 [M+H+] 266.1181; observed 266.1173.

(4-(1-methyl-1H-indol-2yl)phenyl)methanol 20
To a stirred solution of 19 (250 mg, 0.94 mmol) in anhydrous THF was added LiAlH4 (34 mg, 0.94
mmol) and the temperature gently raised to 40 oC. Another 3-4 eq of LiAlH4 was added in portions
over 20-30 min and the reaction mixture was stirred at 40 oC for a further 3-4 h. The reaction was
monitored by TLC (EtOAc: Pet. spirit, 2:3) and upon completion was slowly quenched by dropwise
addition of saturated aqueous NH4Cl. After cessation of bubbling the mixture was diluted with
water and extracted with EtOAc (3 x 10 mL). The organic layer was dried over anhydrous MgSO4
and concentrated in vacuo to yield 20 as an off-white solid (190 mg, 85%). mp 97-99 oC; 1H NMR
(500 MHz, (CD3)2SO): δ 3.71 (s, 3H), 4.72 (s, 2H), 6.54 (s, 1H), 7.13 (appt, J = 7.5 Hz, 1H), 7.24
(appt, J = 15.5 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H),
7.62 (d, J = 8.0 Hz, 1H); 13C NMR (125 MHz, (CD3)2SO): δ 31.1, 64.9, 101.6, 109.5, 119.8, 120.4,
121.6, 127.0, 127.9, 129.4, 132.1, 138.3, 140.4, 141.2; ESI-MS m/z Calc for C16H16NO [M+H+]
238.1232; observed 238.1224.

2-(4-chloromethyl)phenyl)-1-methyl-1H-indole 21
A solution of alcohol 20 (300 mg, 1.26 mmol) in CCl4:CH2Cl2 (1:2, 7 mL) was stirred for 10 min at
room temperature. PPh3 (991 mg, 3.78 mmol) was then added and stirring continued for 1 h. TLC
analysis (EtOAc:hexane, 1:4) indicated complete consumption of the alcohol. The product was
filtered over a neutral alumina bed and washed with dichloromethane (3 x 5 mL). The combined
filtrates were concentrated in vacuo, ensuring the water bath temperature stays below 40 o C. The
residue obtained was triturated with pentane (3 x 4 mL) to afford crude 21 (210 mg, 65%). The
crude 21 was used immediately and due to its instability was unable to be characterised.

MIC, Checkerboard, Uptake and C. elegans experiments
MIC, checkerboard and uptake measurements with 8325-4 wild-type, K1758 norA-knockout and
K2378 NorA overexpressing S. aureus cells were obtained using the published methods.[2,9,10] MIC
measurements with S. aureus MW2 and E. faecalis MMH594 were obtained as follows. Cultures of
S. aureus MW2 and E. faecalis MMH594 were grown overnight in TSB or BHI broth, respectively,
to stationary phase at 37°C with aeration. The cultures were diluted to an approximate density of 2
x 10-4 CFU/mL in the appropriate worm infection media. 12.5 µL of the bacterial culture dilutions
were inoculated into 384-well plates containing 2-fold serial dilutions (in infection media) of the
compounds being tested. Plates were incubated at 37°C for 15 h and scored by eye for bacterial
growth. Checkerboard MIC experiments with MW2 and MMH594 were carried out in a similar
manner as the MIC experiments with individual compounds as described above, with the exception
that 2-fold serial dilutions of two compounds were arrayed in the 384-well plates in such a way that
all combinations of dilutions between the two compounds were tested.
The C. elegans/MRSA MW2 live infection experiments were carried out according to our
recently published methods.[18] The C. elegans/E. faecalis MMH594 experiments were carried out
using the published procedure[19] with minor modifications. Briefly, a synchronous population of
glp-4(bn2); sek-1(km4) worms were grown to the young adult stage on SK agar plates with E. coli
HB101 lawns. The worms were washed off the HB101 SK plates and transferred onto BHI agar
plates with E. faecalis MMH594 lawns and incubated for 15 h at 15°. Following infection, worms
were resuspended in M9 and dispensed using a COPAS BioSort large particle sorter (Union
Biometrica) into 384-well assay plates that contained compounds in 55 μl of infection assay media.
Total volume per well was 70 µl with the final concentrations of components being 20% BHI, 60%
M9 buffer, 19% sheath solution (Union Biometrica), 80 µg/ml kanamycin, 62.5 U/ml nystatin, and
1% DMSO. The plates were sealed with gas-permeable membranes and incubated at 26.3° with
85% relative humidity (RH) for 5 days without agitation. After 5 days, the plates were washed 5
times using a Biotek ELx405 plate washer, and Sytox Orange (Invitrogen) was added to a final

concentration of 0.7μM. The plates were sealed with gas permeable membranes and incubated at
20°, 80% RH for 16 h. After staining, bright field and red fluorescence images of the wells were
captured using the ImageXpress Micro (Molecular Devices) and worm death was scored from the
images using the image analysis software CellProfiler (www.cellprofiler.com).
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